Sucampo Pharmaceuticals (SCMP) 19.60 $SCMP
Sucampo Announces Second Quarter 2015 Earnings Call
GlobeNewswire - Wed Jul 22, 3:02PM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its second quarter 2015 financial results teleconference and webcast at 8:30 a.m. Eastern on Wednesday, August 5, 2015. The press release announcing the financial results and operating highlights is expected to be released before the opening of capital markets that day.
SCMP: 19.60 (-1.20)
Stocks Stay In Mixed Territory; Sucampo Breaks Out
at Investor's Business Daily - Fri Jul 17, 12:32PM CDT
Stocks continued to trade in split fashion Friday afternoon amid a round of earnings reports and mixed economic data. Thanks to Google (GOOGL), which reported solid Q2 results late Thursday, the tech-heavy Nasdaq continued to hold its 0.5% gain. The...
MLM: 159.28 (-1.56), SCMP: 19.60 (-1.20), GOOGL: 674.73 (-20.37), FLTX: 49.63 (+0.95)
Meet 5 Top-Rated Stocks Poised For Big Profit Gains
at Investor's Business Daily - Wed Jul 08, 7:02AM CDT
With quarterly earnings queuing up to be announced and the stock market under pressure, it's a good time to look over top-rated companies such as Palo Alto Networks (PANW) and Ambarella (AMBA) that are expected to show strong profit growth. Today's...
AMBA: 122.99 (+0.49), GPRO: 63.95 (+2.27), GS: 211.05 (-2.20), JPM: 69.64 (-0.44), SCMP: 19.60 (-1.20), ESNT: 29.16 (-0.27), HAWK: 45.07 (-0.52), TASR: 31.71 (-0.49), DGLY: 11.27 (-0.46), PANW: 197.09 (+4.69)
Sucampo Announces Webcast of Its Presentation at Cantor Fitzgerald's Inaugural Healthcare Conference
GlobeNewswire - Wed Jul 01, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at Cantor Fitzgerald's Inaugural Healthcare Conference taking place July 8, 2015 at 2:00 PM ET.
SCMP: 19.60 (-1.20)
Downtrend Call Working As Sucampo Pharmaceuticals Stock Falls 9.0% (SCMP)
Comtex SmarTrend(R) - Tue Jun 30, 11:47AM CDT
SmarTrend identified a Downtrend for Sucampo Pharmaceuticals (NASDAQ:SCMP) on April 30th, 2015 at $18.08. In approximately 2 months, Sucampo Pharmaceuticals has returned 8.99% as of today's recent price of $16.45.
SCMP: 19.60 (-1.20)
Synergy Longs Now Have The Upper Hand
Scrying Biotech - at Seeking Alpha - Thu Jun 18, 11:54AM CDT
SGYP: 8.42 (-0.14), IRWD: 11.41 (+0.07), SCMP: 19.60 (-1.20)
Synergy shares up on results of study for constipation drug
AP - Wed Jun 17, 8:14AM CDT
NEW YORK (AP) — Shares of Synergy Pharmaceuticals jumped 47 percent before Wednesday's opening bell on encouraging, late-state study results for its constipation drug.
SGYP: 8.42 (-0.14), SCMP: 19.60 (-1.20)
PhRMA Elects New Members of Board of Directors
PR Newswire - Tue Jun 16, 9:00AM CDT
The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced the election of five of its newest members to its Board of Directors.
SCMP: 19.60 (-1.20), HZNP: 38.08 (+0.17), BMY: 68.24 (-1.13)
Buy These 6 Risky Pharmaceutical Stocks for Big Upside Potential
at The Street - Tue Jun 16, 8:08AM CDT
Looking to add even more performance to your portfolio? Consider pharmaceutical stocks with so-called high beta - a common measurement of volatility.
LCI: 58.19 (-1.01), PBH: 47.91 (-0.11), SCMP: 19.60 (-1.20), MYL: 66.56 (-1.34), SCLN: 9.67 (-0.14)
China Food and Drug Administration Accepts IND for Pivotal Study of AMITIZA(R) (lubiprostone)
GlobeNewswire - Mon Jun 15, 3:02PM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that the China Food and Drug Administration (CFDA) has accepted an Investigational New Drug (IND) application for a pivotal study of AMITIZA in patients with chronic idiopathic constipation. Harbin Gloria Pharmaceuticals Co., Ltd. (Gloria) will design and conduct the study under the terms of its exclusive license, development, commercialization and supply agreement with Sucampo for AMITIZA in China. In connection with the IND acceptance, Sucampo will receive $500,000 from Gloria, which is the second tranche of the $1.5 million upfront payment agreed to as part of the licensing agreement.
SCMP: 19.60 (-1.20)
12.8% Return Seen to Date on SmarTrend Sucampo Pharmaceuticals Call (SCMP)
Comtex SmarTrend(R) - Mon Jun 15, 9:24AM CDT
SmarTrend identified a Downtrend for Sucampo Pharmaceuticals (NASDAQ:SCMP) on April 30th, 2015 at $18.08. In approximately 2 months, Sucampo Pharmaceuticals has returned 12.81% as of today's recent price of $15.76.
SCMP: 19.60 (-1.20)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jun 05, 4:37PM CDT
EXXI: 1.76 (+0.12), KMPH: 17.97 (+0.13), DRNA: 13.69 (-0.52), ANTH: 10.91 (+0.14), SCMP: 19.60 (-1.20), CDNA: 7.02 (-0.08), SUPN: 19.98 (-0.15), MRD: 15.48 (-0.13), PLAY: 39.08 (-0.35), PDLI: 6.18 (-0.08)
Shares of SCMP Down 10.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri May 29, 11:41AM CDT
SmarTrend identified a Downtrend for Sucampo Pharmaceuticals (NASDAQ:SCMP) on April 30th, 2015 at $18.08. In approximately 4 weeks, Sucampo Pharmaceuticals has returned 10.82% as of today's recent price of $16.12.
SCMP: 19.60 (-1.20)
Global Portal Hypertension Clinical Trials Report 2015
M2 - Wed May 27, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6pcpq/portal) has announced the addition of the "Portal Hypertension Global Clinical Trials Review, H1, 2015" report to their offering. Portal Hypertension Global Clinical Trials Review, H1, 2015" provides data on the Portal Hypertension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Portal Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Portal Hypertension. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Portal Hypertension Therapeutics Clinical Trials - Genextra S.p.a. - United Therapeutics Corporation - Sucampo Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Dr. Falk Pharma GmbH - Galectin Therapeutics, Inc. - Forest Laboratories, Inc. - Dong-A Socio Group - Conatus Pharmaceuticals Inc. - Chiasma, Inc. Clinical Trial Overview of Top Institutes / Government - Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - Govind Ballabh Pant Hospital - Shandong Provincial Hospital - Aga Khan University - Hospital Clinic de Barcelona - Hanyang University Guri Hospital - Hvidovre University Hospital - Martin-Luther-Universitat Halle-Wittenberg - Medical University of Vienna - Shanghai Sixth People's Hospital For more information visit http://www.researchandmarkets.com/research/j6pcpq/portal
GILD: 117.66 (+0.22), UTHR: 175.10 (+0.50), CNAT: 5.16 (+0.01), SCMP: 19.60 (-1.20), GALT: 2.83 (+0.10)
Sucampo Announces Webcast of Its Presentation at the Jefferies 2015 Healthcare Conference
GlobeNewswire - Wed May 27, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the Jefferies 2015 Healthcare Conference taking place June 3, 2015 at 4:00 PM ET.
SCMP: 19.60 (-1.20)
Global Spinal Stenosis Pipeline Review 2015 - 5 Companies & 6 Drug Profiles
M2 - Wed May 20, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/68zlvw/spinal_stenosis) has announced the addition of the "Spinal Stenosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Stenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Stenosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - LTT Bio-Pharma Co., Ltd. - Mesoblast Limited - Sucampo Pharmaceuticals, Inc. - Toray Industries, Inc. - Yungjin Pharm Ind. Co., Ltd. Drug Profiles - beraprost sodium SR - LT-0101 - MPC-25Osteo - SPI-017 - SPI-3608 - YLS-1501 For more information visit http://www.researchandmarkets.com/research/68...l_stenosis
SCMP: 19.60 (-1.20)
Week In Review: BeiGene Raises $97 Million For Cancer Drugs
ChinaBio Today - at Seeking Alpha - Sun May 17, 2:51AM CDT
Deals and Financings BeiGene, a Beijing biopharma focused on developing novel targeted and immuno-oncology cancer therapies, completed a $97 million fundraising. Six months ago, BeiGene announced a $75 million Series A financing. BeiGene currently...
SCMP: 19.60 (-1.20), WX: 42.71 (+0.06), LLY: 86.76 (+0.38), SCLN: 9.67 (-0.14)
Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week
GlobeNewswire - Fri May 15, 3:02PM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for lubiprostone will be presented at Digestive Disease Week ("DDW"
2015 in Washington, D.C. Information regarding the presentations can be found below.
SCMP: 19.60 (-1.20)
Sucampo Announces Second Quarter 2015 Earnings Call
GlobeNewswire - Wed Jul 22, 3:02PM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its second quarter 2015 financial results teleconference and webcast at 8:30 a.m. Eastern on Wednesday, August 5, 2015. The press release announcing the financial results and operating highlights is expected to be released before the opening of capital markets that day.
SCMP: 19.60 (-1.20)
Stocks Stay In Mixed Territory; Sucampo Breaks Out
at Investor's Business Daily - Fri Jul 17, 12:32PM CDT
Stocks continued to trade in split fashion Friday afternoon amid a round of earnings reports and mixed economic data. Thanks to Google (GOOGL), which reported solid Q2 results late Thursday, the tech-heavy Nasdaq continued to hold its 0.5% gain. The...
MLM: 159.28 (-1.56), SCMP: 19.60 (-1.20), GOOGL: 674.73 (-20.37), FLTX: 49.63 (+0.95)
Meet 5 Top-Rated Stocks Poised For Big Profit Gains
at Investor's Business Daily - Wed Jul 08, 7:02AM CDT
With quarterly earnings queuing up to be announced and the stock market under pressure, it's a good time to look over top-rated companies such as Palo Alto Networks (PANW) and Ambarella (AMBA) that are expected to show strong profit growth. Today's...
AMBA: 122.99 (+0.49), GPRO: 63.95 (+2.27), GS: 211.05 (-2.20), JPM: 69.64 (-0.44), SCMP: 19.60 (-1.20), ESNT: 29.16 (-0.27), HAWK: 45.07 (-0.52), TASR: 31.71 (-0.49), DGLY: 11.27 (-0.46), PANW: 197.09 (+4.69)
Sucampo Announces Webcast of Its Presentation at Cantor Fitzgerald's Inaugural Healthcare Conference
GlobeNewswire - Wed Jul 01, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at Cantor Fitzgerald's Inaugural Healthcare Conference taking place July 8, 2015 at 2:00 PM ET.
SCMP: 19.60 (-1.20)
Downtrend Call Working As Sucampo Pharmaceuticals Stock Falls 9.0% (SCMP)
Comtex SmarTrend(R) - Tue Jun 30, 11:47AM CDT
SmarTrend identified a Downtrend for Sucampo Pharmaceuticals (NASDAQ:SCMP) on April 30th, 2015 at $18.08. In approximately 2 months, Sucampo Pharmaceuticals has returned 8.99% as of today's recent price of $16.45.
SCMP: 19.60 (-1.20)
Synergy Longs Now Have The Upper Hand
Scrying Biotech - at Seeking Alpha - Thu Jun 18, 11:54AM CDT
SGYP: 8.42 (-0.14), IRWD: 11.41 (+0.07), SCMP: 19.60 (-1.20)
Synergy shares up on results of study for constipation drug
AP - Wed Jun 17, 8:14AM CDT
NEW YORK (AP) — Shares of Synergy Pharmaceuticals jumped 47 percent before Wednesday's opening bell on encouraging, late-state study results for its constipation drug.
SGYP: 8.42 (-0.14), SCMP: 19.60 (-1.20)
PhRMA Elects New Members of Board of Directors
PR Newswire - Tue Jun 16, 9:00AM CDT
The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced the election of five of its newest members to its Board of Directors.
SCMP: 19.60 (-1.20), HZNP: 38.08 (+0.17), BMY: 68.24 (-1.13)
Buy These 6 Risky Pharmaceutical Stocks for Big Upside Potential
at The Street - Tue Jun 16, 8:08AM CDT
Looking to add even more performance to your portfolio? Consider pharmaceutical stocks with so-called high beta - a common measurement of volatility.
LCI: 58.19 (-1.01), PBH: 47.91 (-0.11), SCMP: 19.60 (-1.20), MYL: 66.56 (-1.34), SCLN: 9.67 (-0.14)
China Food and Drug Administration Accepts IND for Pivotal Study of AMITIZA(R) (lubiprostone)
GlobeNewswire - Mon Jun 15, 3:02PM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that the China Food and Drug Administration (CFDA) has accepted an Investigational New Drug (IND) application for a pivotal study of AMITIZA in patients with chronic idiopathic constipation. Harbin Gloria Pharmaceuticals Co., Ltd. (Gloria) will design and conduct the study under the terms of its exclusive license, development, commercialization and supply agreement with Sucampo for AMITIZA in China. In connection with the IND acceptance, Sucampo will receive $500,000 from Gloria, which is the second tranche of the $1.5 million upfront payment agreed to as part of the licensing agreement.
SCMP: 19.60 (-1.20)
12.8% Return Seen to Date on SmarTrend Sucampo Pharmaceuticals Call (SCMP)
Comtex SmarTrend(R) - Mon Jun 15, 9:24AM CDT
SmarTrend identified a Downtrend for Sucampo Pharmaceuticals (NASDAQ:SCMP) on April 30th, 2015 at $18.08. In approximately 2 months, Sucampo Pharmaceuticals has returned 12.81% as of today's recent price of $15.76.
SCMP: 19.60 (-1.20)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jun 05, 4:37PM CDT
EXXI: 1.76 (+0.12), KMPH: 17.97 (+0.13), DRNA: 13.69 (-0.52), ANTH: 10.91 (+0.14), SCMP: 19.60 (-1.20), CDNA: 7.02 (-0.08), SUPN: 19.98 (-0.15), MRD: 15.48 (-0.13), PLAY: 39.08 (-0.35), PDLI: 6.18 (-0.08)
Shares of SCMP Down 10.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri May 29, 11:41AM CDT
SmarTrend identified a Downtrend for Sucampo Pharmaceuticals (NASDAQ:SCMP) on April 30th, 2015 at $18.08. In approximately 4 weeks, Sucampo Pharmaceuticals has returned 10.82% as of today's recent price of $16.12.
SCMP: 19.60 (-1.20)
Global Portal Hypertension Clinical Trials Report 2015
M2 - Wed May 27, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6pcpq/portal) has announced the addition of the "Portal Hypertension Global Clinical Trials Review, H1, 2015" report to their offering. Portal Hypertension Global Clinical Trials Review, H1, 2015" provides data on the Portal Hypertension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Portal Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Portal Hypertension. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Portal Hypertension Therapeutics Clinical Trials - Genextra S.p.a. - United Therapeutics Corporation - Sucampo Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Dr. Falk Pharma GmbH - Galectin Therapeutics, Inc. - Forest Laboratories, Inc. - Dong-A Socio Group - Conatus Pharmaceuticals Inc. - Chiasma, Inc. Clinical Trial Overview of Top Institutes / Government - Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - Govind Ballabh Pant Hospital - Shandong Provincial Hospital - Aga Khan University - Hospital Clinic de Barcelona - Hanyang University Guri Hospital - Hvidovre University Hospital - Martin-Luther-Universitat Halle-Wittenberg - Medical University of Vienna - Shanghai Sixth People's Hospital For more information visit http://www.researchandmarkets.com/research/j6pcpq/portal
GILD: 117.66 (+0.22), UTHR: 175.10 (+0.50), CNAT: 5.16 (+0.01), SCMP: 19.60 (-1.20), GALT: 2.83 (+0.10)
Sucampo Announces Webcast of Its Presentation at the Jefferies 2015 Healthcare Conference
GlobeNewswire - Wed May 27, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the Jefferies 2015 Healthcare Conference taking place June 3, 2015 at 4:00 PM ET.
SCMP: 19.60 (-1.20)
Global Spinal Stenosis Pipeline Review 2015 - 5 Companies & 6 Drug Profiles
M2 - Wed May 20, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/68zlvw/spinal_stenosis) has announced the addition of the "Spinal Stenosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Stenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Stenosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - LTT Bio-Pharma Co., Ltd. - Mesoblast Limited - Sucampo Pharmaceuticals, Inc. - Toray Industries, Inc. - Yungjin Pharm Ind. Co., Ltd. Drug Profiles - beraprost sodium SR - LT-0101 - MPC-25Osteo - SPI-017 - SPI-3608 - YLS-1501 For more information visit http://www.researchandmarkets.com/research/68...l_stenosis
SCMP: 19.60 (-1.20)
Week In Review: BeiGene Raises $97 Million For Cancer Drugs
ChinaBio Today - at Seeking Alpha - Sun May 17, 2:51AM CDT
Deals and Financings BeiGene, a Beijing biopharma focused on developing novel targeted and immuno-oncology cancer therapies, completed a $97 million fundraising. Six months ago, BeiGene announced a $75 million Series A financing. BeiGene currently...
SCMP: 19.60 (-1.20), WX: 42.71 (+0.06), LLY: 86.76 (+0.38), SCLN: 9.67 (-0.14)
Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week
GlobeNewswire - Fri May 15, 3:02PM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for lubiprostone will be presented at Digestive Disease Week ("DDW"
2015 in Washington, D.C. Information regarding the presentations can be found below. SCMP: 19.60 (-1.20)
